[Ever Supreme Bio] Shareholders approve waiver of non-compete restrictions for directors
At the 2026/05/20 shareholder meeting, Ever Supreme Bio Technology approved the waiver of non-compete restrictions for its directors and independent directors. The resolution passed with a majority vote in accordance with Article 209 of the Company Act and has no material impact on the company's financial operations.
📋 Article Processing Timeline
- 📰 Published: May 20, 2026 at 09:00
- 🔍 Collected: May 21, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 21, 2026 at 08:36 (36 min after Collected)
1. Date of shareholder resolution: 2026/05/20
2. Name and title of directors permitted to engage in competitive business:
Director: Hsieh Hsiu-mei (Representative of Qi Teng Co., Ltd.)
Director: Chang Chia-fang
Director: Ling Mei-hua
Independent Director: Chen Cheng-jen
Independent Director: Su Chun-yuan
3. Items permitted for competitive business: Duties related to current concurrent roles that fall under non-compete restrictions.
4. Period of permission: During the tenure as a director of the company.
5. Voting status (based on Article 209 of the Company Act): Shareholders representing at least two-thirds of total issued shares attended, and the motion was approved by a majority of the voting rights present.
6. Directors with competitive business in Mainland China (if not applicable, state 'N/A'): N/A.
7. Name and title in the Mainland China entity: N/A.
8. Address of the Mainland China entity: N/A.
9. Business items of the Mainland China entity: N/A.
10. Impact on the company's financial condition and business: No material impact.
11. Investment amount and shareholding ratio in Mainland China entity: N/A.
12. Other items to disclose: None.
2. Name and title of directors permitted to engage in competitive business:
Director: Hsieh Hsiu-mei (Representative of Qi Teng Co., Ltd.)
Director: Chang Chia-fang
Director: Ling Mei-hua
Independent Director: Chen Cheng-jen
Independent Director: Su Chun-yuan
3. Items permitted for competitive business: Duties related to current concurrent roles that fall under non-compete restrictions.
4. Period of permission: During the tenure as a director of the company.
5. Voting status (based on Article 209 of the Company Act): Shareholders representing at least two-thirds of total issued shares attended, and the motion was approved by a majority of the voting rights present.
6. Directors with competitive business in Mainland China (if not applicable, state 'N/A'): N/A.
7. Name and title in the Mainland China entity: N/A.
8. Address of the Mainland China entity: N/A.
9. Business items of the Mainland China entity: N/A.
10. Impact on the company's financial condition and business: No material impact.
11. Investment amount and shareholding ratio in Mainland China entity: N/A.
12. Other items to disclose: None.
FAQ
What is a waiver of non-compete restrictions for directors?
Under company law, directors are restricted from engaging in competing businesses. However, this restriction can be waived through shareholder approval.
Why did Ever Supreme Bio hold this resolution?
It was held to comply with legal requirements, ensuring that directors can officially hold concurrent positions in other organizations.
Are there any impacts from this waiver?
According to the company, the waiver has no material impact on its financial condition or operations.